Table 2—

Secondary end-points

Control groupIloprost groupp-value
NYHA class+0.1±0.3-0.1±0.20.64
VO2,peak0±2-1±20.14
VE/VCO2 at AT+1±8-1±50.65
Peak SAP-6±15-3±220.45
QoL-3±11+7±190.14
Clinical worsening n43ND
  • Data are presented as mean±sd, unless otherwise stated. NYHA: New York Heart Association; V’O2,peak: peak oxygen uptake; VE/VCO2 at AT: ventilatory efficacy; SAP: systolic arterial pressure; QoL: quality of life; ND: not done.